HCW Biologics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hing C. Wong
- Full Time Employees
- 36
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2929 North Commerce Parkway Miramar FL United States of America 33025
- IPO Date
- Jul 20, 2021
- CIK
- 0001828673
- Website
- hcwbiologics.com
- Similar Companies
- Business
- HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to extend the human health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company utilizes its proprietary Tissue factOr-Based fusion (TOBI) discovery platform to generate innovative multi-functional fusion molecules with immunotherapeutic properties. Its main product candidates include HCW9218, a bifunctional immunotherapeutic targeting senescent cells and the senescence-associated secretory phenotype (SASP) factors; HCW9302, designed to activate and expand regulatory T cells to deactivate inflammasomes; and additional candidates such as HCW9201, HCW9206, and HCW11-040, with applications across cancer, cardiovascular diseases, diabetes, neurodegenerative disorders, autoimmune diseases, and long-haul COVID-19. Founded in 2018 and headquartered in Miramar, Florida, HCW Biologics conducts clinical trials and advances drug development aimed at counteracting age-related chronic inflammation, serving global markets. Recent significant developments include the initiation of a multi-center, first-in-human Phase 1 clinical trial of HCW9302 for alopecia areata at The Ohio State University Wexner Medical Center, announced in late 2025. The company also completed a $4 million warrant inducement financing and issued shares under a standby equity purchase agreement to secure ongoing funding. HCW Biologics presented preclinical data for its tetra-valent pembrolizumab-based immune checkpoint inhibitor HCW11-040 and enhancements in its T-Cell Engager (TCE) programs at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, showcasing advances in immune modulation and tumor activity. HCW Biologics leverages strategic partnerships and academic collaborations to accelerate research and development efforts in immunotherapies addressing unmet medical needs related to aging and immune system dysfunction. The company operates within the biotechnology and pharmaceuticals sectors, targeting healthcare providers, research institutions, and pharmaceutical partners worldwide. Its continued focus on innovative fusion protein therapeutics positions HCW Biologics as a developer of next-generation immunotherapies in age-associated disease management and immune system rejuvenation.
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
Reviewing HCW Biologics (NASDAQ:HCWB) and ImmunityBio (NASDAQ:IBRX)
Analyzing Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) & HCW Biologics (NASDAQ:HCWB)
HCW Biologics (NASDAQ:HCWB) Trading Down 7.1% – Here’s What Happened
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results